Sudarshan Pharma Industries Ltd Allots 90,00,000 Equity Shares Upon Warrant Conversion

On Friday, shares of Sudarshan Pharma Industries Ltd closed at Rs 35.70, up 1.80 per cent from its previous closing price of Rs 35.07 per share. The stock touched an Intraday high of Rs 35.90, representing a gain of about 2.37 per cent from the previous close. The stock’s 52-week high stands at Rs 36.95 per share, while its 52-week low is Rs 18.50 per share.

Sudarshan Pharma Industries Ltd informed exchanges that the Warrants Committee of the Board of Directors, at its meeting held on Friday, June 12, 2026, approved the allotment of 90,00,000 equity shares of face value Re 1 each pursuant to the exercise of warrants that were previously issued on a preferential basis.

The company allotted the equity shares at an issue price of Rs 16.983 per share, including a premium of Rs 15.983 per share. The allotment was made following the conversion of 9,00,000 warrants issued at an issue price of Rs 169.83 per warrant to persons belonging to the promoter category.

The conversion was completed after the company received the balance consideration amount aggregating to Rs 11,46,35,250 from the allottees. The balance payment was made at the rate of Rs 127.37 per warrant, which represents 75 per cent of the issue price per warrant, in accordance with the terms of the preferential issue.

The company stated that, pursuant to the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the number of shares, paid-up capital per share and premium per share have been appropriately adjusted following the subdivision of shares approved by shareholders through a postal ballot announced on November 5, 2024.

According to the company, the newly allotted equity shares will rank pari-passu with the existing equity shares in all respects.

Following the allotment, the issued and paid-up share capital of Sudarshan Pharma Industries Ltd has increased to Rs 24,96,59,870, comprising 24,96,59,870 equity shares of Re 1 each.

The company has made the disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with the relevant provisions of the SEBI Master Circular dated November 11, 2024.

The company has a market cap of over Rs 859.15 crore. The stock price has surged over 30 per cent in the last one year.

The stock has delivered returns of about 92.97 per cent from its 52-week low of Rs 18.50 per share.

Disclaimer: The article is for informational purposes only and not investment advice.

What are your views on Sudarshan Pharma Industries Ltd after this preferential allotment and warrant conversion? Share your thoughts in the comments below.